Norethindrone Acetate (Norlutate)

01/01/2012 - "Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. "
06/01/2017 - "To study the efficacy of long-term treatment with norethindrone acetate (NETA) in patients with rectovaginal endometriosis. "
01/01/2012 - "Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma. "
06/01/2017 - "Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis."
01/01/2014 - "In women with rectovaginal lesions or colorectal endometriosis, norethisterone acetate at low dosage should be preferred. "

04/01/2015 - "Women treated with up to 4 courses of UA (10 mg/day for 3 months) followed or not by norethisterone acetate (10 mg/day for 10 days or placebo) reported a high rate of bleeding control, and improved quality of life, pain anxiety and depression. "
01/01/2010 - "This pilot study evaluates the efficacy of norethisterone acetate in treating pain and gastrointestinal symptoms of women with colorectal endometriosis. "
01/01/2010 - "In some patients with bowel endometriosis, the administration of norethisterone acetate may determine a relief of pain and gastrointestinal symptoms. "
07/01/2003 - "The analyses of Hornstein et al. 1998 and Surrey et al. 2002 clearly demonstrate that a significant reduction in pain with few side effects results when from the first day of treatment with leuprolide acetate depot an add-back scheme of 5 mg norethindrone acetate per day is applied."
01/01/2018 - "The purpose of this study was to assess the proportion of patients satisfied with their treatment after a change from a low-dose oral contraceptive (OC) to norethisterone acetate (NETA) because of inefficacy of OC on pain symptoms. "

09/01/2000 - "In study 1, there was a significantly greater relative risk (RR) for bleeding in the group receiving 1 mg norethindrone acetate/10 microg ethinyl E2 at study weeks 4 and 8 (RR = 1.36 and 95% confidence interval [CI] 1.01, 1.83; RR = 1.37 and 95% CI 1.1, 1.72; respectively) compared with placebo, but not at study weeks 12 or 16. "
01/01/2023 - "Almost all patients had improved bleeding at T2 (96% for norethindrone acetate and 100% for IUD users), with no difference between subgroups. "
09/01/1999 - "After the initial 3 months of treatment, bleeding profiles improved with increasing doses of norethindrone acetate."
03/01/2009 - "In contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC."
06/13/2022 - "Women rated bleeding quantity and frequency at four intervals, at weeks 0, 2, 4, and 6. (3) Results: Women who added 5 mg norethisterone acetate reported a significant decrease in bleeding frequency compared to the other groups, observed after 2, 4, and 6 weeks (p-values 0.019, 0.002, and 0.002, respectively). "

08/28/2023 - "Patients with obesity or heavy menstrual bleeding may achieve suppression with higher doses of norethindrone acetate. "
04/01/2022 - "Food and Drug Administration (FDA) in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with UFs in premenopausal women. "
01/01/2022 - "Elagolix appeared to be effective in reducing heavy menstrual bleeding caused by uterine fibroid and combination with estradiol/norethindrone acetate was able to alleviate the hypoestrogenism side effects in premenopausal women. "
03/01/2022 - "An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women."
01/01/2022 - "This systematic review and meta-analysis aimed to determine the effectiveness of elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid by comparing: elagolix versus placebo and elagolix versus estradiol/norethindrone acetate. "

02/01/1964 - "ACUTE HEMORRHAGIC DEGENERATION OF A LEIOMYOMA FOLLOWING NORETHINDRONE ACETATE: REPORT OF A CASE."
11/23/2020 - "Because of very low-quality evidence, we are uncertain whether the LNG-IUS reduces abnormal uterine bleeding or increases haemoglobin levels in premenopausal women with uterine fibroids, compared to COC or norethisterone acetate. "
12/01/2022 - "These drugs, alone and in combination with E2/NETA (estradiol/norethindrone acetate), showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life in premenopausal patients with symptomatic uterine fibroids. "
05/01/2023 - "Ultrasound-Guided Diagnosis of Multiple Uterine Fibroids in a Patient With Polycystic Ovaries and Treatment With Relugolix, Estradiol, and Norethisterone Acetate."
10/01/2022 - "With its convenient once-daily administration, relugolix/estradiol/norethisterone acetate is a useful addition to current medical treatment options for premenopausal women with symptomatic uterine fibroids."